Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Michael Caligiuri

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Anatomy

Living Beings

Chemicals & Drugs

Disorders

Procedures

Immunotherapy

Physiology

Lymphocyte Activation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Yu Jianhua; Wei Min; Mao Hsiaoyin; Zhang Jianying; Hughes Tiffany; Mitsui Takeki; Park Il-kyoo; Hwang Christine; Liu Shujun; Marcucci Guido; Trotta Rossana; Benson Don M; Caligiuri Michael A
CD94 defines phenotypically and functionally distinct mouse NK cell subsets.
Mani Aruna; Roda Julie; Young Donn; Caligiuri Michael A; Fleming Gini F; Kaufman Peter; Brufsky Adam; Ottman Susan; Carson William E; Shapiro Charles L
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Langer Christian; Marcucci Guido; Holland Kelsi B; Radmacher Michael D; Maharry Kati; Paschka Peter; Whitman Susan P; Mrózek Krzysztof; Baldus Claudia D; Vij Ravi; Powell Bayard L; Carroll Andrew J; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Caligiuri (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Yu Jianhua; Wei Min; Mao Hsiaoyin; Zhang Jianying; Hughes Tiffany; Mitsui Takeki; Park Il-kyoo; Hwang Christine; Liu Shujun; Marcucci Guido; Trotta Rossana; Benson Don M; Caligiuri Michael A
CD94 defines phenotypically and functionally distinct mouse NK cell subsets.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(8):4968-74.
2009: Mani Aruna; Roda Julie; Young Donn; Caligiuri Michael A; Fleming Gini F; Kaufman Peter; Brufsky Adam; Ottman Susan; Carson William E; Shapiro Charles L
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Breast cancer research and treatment 2009;117(1):83-9.
2009: Langer Christian; Marcucci Guido; Holland Kelsi B; Radmacher Michael D; Maharry Kati; Paschka Peter; Whitman Susan P; Mrózek Krzysztof; Baldus Claudia D; Vij Ravi; Powell Bayard L; Carroll Andrew J; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3198-204.
2009: Yu Jianhua; Ershler Maxim; Yu Li; Wei Min; Hackanson Björn; Yokohama Akihiko; Mitsui Takeki; Liu Chunhui; Mao Hsiaoyin; Liu Shujun; Liu Zhongfa; Trotta Rossana; Liu Chang-gong; Liu Xiuping; Huang Kun; Visser Jan; Marcucci Guido; Plass Christoph; Belyavsky Alexander V; Caligiuri Michael A
TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.
Blood 2009;113(22):5558-67.
2009: Woyach J A; Lin T S; Lucas M S; Heerema N; Moran M E; Cheney C; Lucas D M; Wei L; Caligiuri M A; Byrd J C
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):912-8.
2009: Hughes Tiffany; Becknell Brian; McClory Susan; Briercheck Edward; Freud Aharon G; Zhang Xiaoli; Mao Hsiaoyin; Nuovo Gerard; Yu Jianhua; Caligiuri Michael A
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.
Blood 2009;113(17):4008-10.
2009: Lapalombella Rosa; Gowda Aruna; Joshi Trupti; Mehter Najma; Cheney Carolyn; Lehman Amy; Chen Ching-Shih; Johnson Amy J; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
British journal of haematology 2009;144(6):848-55.
2009: Benson Don M; Yu Jianhua; Becknell Brian; Wei Min; Freud Aharon G; Ferketich Amy K; Trotta Rossana; Perrotti Danilo; Briesewitz Roger; Caligiuri Michael A
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.
Blood 2009;113(12):2706-14.
2009: Park Il-Kyoo; Giovenzana Chiara; Hughes Tiffany L; Yu Jianhua; Trotta Rossana; Caligiuri Michael A
The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.
Blood 2009;113(11):2470-7.
2008: Marcucci Guido; Maharry Kati; Radmacher Michael D; Mrózek Krzysztof; Vukosavljevic Tamara; Paschka Peter; Whitman Susan P; Langer Christian; Baldus Claudia D; Liu Chang-Gong; Ruppert Amy S; Powell Bayard L; Carroll Andrew J; Caligiuri Michael A; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5078-87.
2008: Becknell Brian; Caligiuri Michael A
Natural killer cells in innate immunity and cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):685-92.
2008: Baer Maria R; George Stephen L; Caligiuri Michael A; Sanford Ben L; Bothun Sandra M; Mrózek Krzysztof; Kolitz Jonathan E; Powell Bayard L; Moore Joseph O; Stone Richard M; Anastasi John; Bloomfield Clara D; Larson Richard A
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4934-9.
2008: Paschka Peter; Marcucci Guido; Ruppert Amy S; Whitman Susan P; Mrózek Krzysztof; Maharry Kati; Langer Christian; Baldus Claudia D; Zhao Weiqiang; Powell Bayard L; Baer Maria R; Carroll Andrew J; Caligiuri Michael A; Kolitz Jonathan E; Larson Richard A; Bloomfield Clara D
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4595-602.
2008: Trotta Rossana; Col Jessica Dal; Yu Jianhua; Ciarlariello David; Thomas Brittany; Zhang Xiaoli; Allard Jeffrey; Wei Min; Mao Hsiaoyin; Byrd John C; Perrotti Danilo; Caligiuri Michael A
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(6):3784-92.
2008: Dorrance Adrienne M; Liu Shujun; Chong Anita; Pulley Benjamin; Nemer David; Guimond Martin; Yuan Weifeng; Chang Dennis; Whitman Susan P; Marcucci Guido; Caligiuri Michael A
The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.
Blood 2008;112(6):2508-11.
2008: Whitman Susan P; Hackanson Björn; Liyanarachchi Sandya; Liu Shujun; Rush Laura J; Maharry Kati; Margeson Dean; Davuluri Ramana; Wen Jing; Witte Tatiana; Yu Li; Liu Chunhui; Bloomfield Clara D; Marcucci Guido; Plass Christoph; Caligiuri Michael A
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Blood 2008;112(5):2013-6.
2008: Caligiuri Michael A
Human natural killer cells.
Blood 2008;112(3):461-9.
2008: Marcucci Guido; Radmacher Michael D; Maharry Kati; Mrózek Krzysztof; Ruppert Amy S; Paschka Peter; Vukosavljevic Tamara; Whitman Susan P; Baldus Claudia D; Langer Christian; Liu Chang-Gong; Carroll Andrew J; Powell Bayard L; Garzon Ramiro; Croce Carlo M; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008;358(18):1919-28.
2008: Gowda Aruna; Roda Julie; Hussain Syed-Rehan A; Ramanunni Asha; Joshi Trupti; Schmidt Susan; Zhang Xiaoli; Lehman Amy; Jarjoura David; Carson William E; Kindsvogel Wayne; Cheney Carolyn; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
Blood 2008;111(9):4723-30.
2008: Kondadasula Sri Vidya; Roda Julie M; Parihar Robin; Yu Jianhua; Lehman Amy; Caligiuri Michael A; Tridandapani Susheela; Burry Richard W; Carson William E
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
Blood 2008;111(8):4173-83.
2008: Liu Shujun; Liu Zhongfa; Xie Zhiliang; Pang Jiuxia; Yu Jianhua; Lehmann Esther; Huynh Lenguyen; Vukosavljevic Tamara; Takeki Mitsui; Klisovic Rebecca B; Baiocchi Robert A; Blum William; Porcu Pierluigi; Garzon Ramiro; Byrd John C; Perrotti Danilo; Caligiuri Michael A; Chan Kenneth K; Wu Lai-Chu; Marcucci Guido
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Blood 2008;111(4):2364-73.
2008: Whitman Susan P; Ruppert Amy S; Radmacher Michael D; Mrózek Krzysztof; Paschka Peter; Langer Christian; Baldus Claudia D; Wen Jing; Racke Frederick; Powell Bayard L; Kolitz Jonathan E; Larson Richard A; Caligiuri Michael A; Marcucci Guido; Bloomfield Clara D
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
Blood 2008;111(3):1552-9.
2008: Lapalombella Rosa; Zhao Xiaobin; Triantafillou Georgia; Yu Bo; Jin Yan; Lozanski Gerard; Cheney Carolyn; Heerema Nyla; Jarjoura David; Lehman Amy; Lee L James; Marcucci Guido; Lee Robert J; Caligiuri Michael A; Muthusamy Natarajan; Byrd John C
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):569-78.
2008: Eiring Anna M; Neviani Paolo; Santhanam Ramasamy; Oaks Joshua J; Chang Ji Suk; Notari Mario; Willis William; Gambacorti-Passerini Carlo; Volinia Stefano; Marcucci Guido; Caligiuri Michael A; Leone Gustavo W; Perrotti Danilo
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Blood 2008;111(2):816-28.
2008: Richards John; McNally Beth; Fang Xianfeng; Caligiuri Michael A; Zheng Pan; Liu Yang
Tumor growth decreases NK and B cells as well as common lymphoid progenitor.
PloS one 2008;3(9):e3180.
2007: Trotta Rossana; Ciarlariello David; Dal Col Jessica; Allard Jeffrey; Neviani Paolo; Santhanam Ramasamy; Mao Hsiaoyin; Becknell Brian; Yu Jianhua; Ferketich Amy K; Thomas Brittany; Modi Aalok; Blaser Bradley W; Perrotti Danilo; Caligiuri Michael A
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.
The Journal of experimental medicine 2007;204(10):2397-405.
2007: Zhao Xiaobin; Lapalombella Rosa; Joshi Trupti; Cheney Carolyn; Gowda Aruna; Hayden-Ledbetter Martha S; Baum Peter R; Lin Thomas S; Jarjoura David; Lehman Amy; Kussewitt Donna; Lee Robert J; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan; Byrd John C
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
Blood 2007;110(7):2569-77.
2007: Opavsky Rene; Tsai Shih-Yin; Guimond Martin; Arora Anjulie; Opavska Jana; Becknell Brian; Kaufmann Michael; Walton Nathaniel A; Stephens Julie A; Fernandez Soledad A; Muthusamy Natarajan; Felsher Dean W; Porcu Pierluigi; Caligiuri Michael A; Leone Gustavo
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(39):15400-5.
2007: Neviani Paolo; Santhanam Ramasamy; Oaks Joshua J; Eiring Anna M; Notari Mario; Blaser Bradley W; Liu Shujun; Trotta Rossana; Muthusamy Natarajan; Gambacorti-Passerini Carlo; Druker Brian J; Cortes Jorge; Marcucci Guido; Chen Ching-Shih; Verrills Nicole M; Roy Denis C; Caligiuri Michael A; Bloomfield Clara D; Byrd John C; Perrotti Danilo
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
The Journal of clinical investigation 2007;117(9):2408-21.
2007: Yu Jianhua; Wei Min; Boyd Zachary; Lehmann Esther B; Trotta Rossana; Mao Hsiaoyin; Liu Shujun; Becknell Brian; Jaung Michael S; Jarjoura David; Marcucci Guido; Wu Lai-Chu; Caligiuri Michael A
Transcriptional control of human T-BET expression: the role of Sp1.
European journal of immunology 2007;37(9):2549-61.
2007: Wang Lisheng; Wang Jie; Blaser Bradley W; Duchemin Anne-Marie; Kusewitt Donna F; Liu Tom; Caligiuri Michael A; Briesewitz Roger
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Blood 2007;110(6):2075-83.
2007: Caligiuri Michael A; Briesewitz Roger; Yu Jianhua; Wang Lisheng; Wei Min; Arnoczky Kristy J; Marburger Trent B; Wen Jing; Perrotti Danilo; Bloomfield Clara D; Whitman Susan P
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Blood 2007;110(3):1022-4.
2007: Chang Ji Suk; Santhanam Ramasamy; Trotta Rossana; Neviani Paolo; Eiring Anna M; Briercheck Edward; Ronchetti Mattia; Roy Denis C; Calabretta Bruno; Caligiuri Michael A; Perrotti Danilo
High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
Blood 2007;110(3):994-1003.
2007: Whitman Susan P; Ruppert Amy S; Marcucci Guido; Mrózek Krzysztof; Paschka Peter; Langer Christian; Baldus Claudia D; Wen Jing; Vukosavljevic Tamara; Powell Bayard L; Carroll Andrew J; Kolitz Jonathan E; Larson Richard A; Caligiuri Michael A; Bloomfield Clara D
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
Blood 2007;109(12):5164-7.
2007: Hussain Syed-Rehan A; Cheney Carolyn M; Johnson Amy J; Lin Thomas S; Grever Michael R; Caligiuri Michael A; Lucas David M; Byrd John C
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2144-50.
2007: Becknell Brian; Hughes Tiffany L; Freud Aharon G; Blaser Bradley W; Yu Jianhua; Trotta Rossana; Mao Hsiaoyin C; Caligiuri de Jesús Marie L; Alghothani Mohamad; Benson Don M; Lehman Amy; Jarjoura David; Perrotti Danilo; Bates Michael D; Caligiuri Michael A
Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.
Blood 2007;109(6):2481-7.
2006: Khan Khuda D; Emmanouilides Christos; Benson Don M; Hurst Deborah; Garcia Pablo; Michelson Glenn; Milan Sandra; Ferketich Amy K; Piro Lawrence; Leonard John P; Porcu Pierluigi; Eisenbeis Charles F; Banks Amy L; Chen Lei; Byrd John C; Caligiuri Michael A
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7046-53.
2006: Freud Aharon G; Caligiuri Michael A
Human natural killer cell development.
Immunological reviews 2006;214():56-72.
2006: Dorrance Adrienne M; Liu Shujun; Yuan Weifeng; Becknell Brian; Arnoczky Kristy J; Guimond Martin; Strout Matthew P; Feng Lan; Nakamura Tatsuya; Yu Li; Rush Laura J; Weinstein Michael; Leone Gustavo; Wu Lizhao; Ferketich Amy; Whitman Susan P; Marcucci Guido; Caligiuri Michael A
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.
The Journal of clinical investigation 2006;116(10):2707-16.
2006: Blaser Bradley W; Schwind Noah R; Karol Seth; Chang Dennis; Shin Samuel; Roychowdhury Sameek; Becknell Brian; Ferketich Amy K; Kusewitt Donna F; Blazar Bruce R; Caligiuri Michael A
Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.
Blood 2006;108(7):2463-9.
2006: Radmacher Michael D; Marcucci Guido; Ruppert Amy S; Mrózek Krzysztof; Whitman Susan P; Vardiman James W; Paschka Peter; Vukosavljevic Tamara; Baldus Claudia D; Kolitz Jonathan E; Caligiuri Michael A; Larson Richard A; Bloomfield Clara D;
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
Blood 2006;108(5):1677-83.
2006: Fulci Giulia; Breymann Laura; Gianni Davide; Kurozomi Kazuhiko; Rhee Sarah S; Yu Jianhua; Kaur Balveen; Louis David N; Weissleder Ralph; Caligiuri Michael A; Chiocca E Antonio
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(34):12873-8.
2006: Farag Sherif S; Bacigalupo Andrea; Eapen Mary; Hurley Carolyn; Dupont Bo; Caligiuri Michael A; Boudreau Christian; Nelson Gene; Oudshoorn Machteld; van Rood Jon; Velardi Andrea; Maiers Martin; Setterholm Michelle; Confer Dennis; Posch Phillip E; Anasetti Claudio; Kamani Naynesh; Miller Jeffrey S; Weisdorf Daniel; Davies Stella M;
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(8):876-84.
2006: Shah Manisha H; Freud Aharon G; Benson Don M; Ferkitich Amy K; Dezube Bruce J; Bernstein Zale P; Caligiuri Michael A
A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):3993-6.
2006: Richards John O; Chang Xing; Blaser Bradley W; Caligiuri Michael A; Zheng Pan; Liu Yang
Tumor growth impedes natural-killer-cell maturation in the bone marrow.
Blood 2006;108(1):246-52.
2006: Ganesan Latha P; Joshi Trupti; Fang Huiqing; Kutala Vijay Kumar; Roda Julie; Trotta Rossana; Lehman Amy; Kuppusamy Periannan; Byrd John C; Carson William E; Caligiuri Michael A; Tridandapani Susheela
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.
Blood 2006;108(2):718-25.
2006: Bloomfield Clara D; Mrózek Krzysztof; Caligiuri Michael A
Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3564s-71s.
2006: Yu Jianhua; Wei Min; Becknell Brian; Trotta Rossana; Liu Shujun; Boyd Zachary; Jaung Michael S; Blaser Bradley W; Sun Jin; Benson Don M; Mao Hsiaoyin; Yokohama Akihiko; Bhatt Darshna; Shen Lei; Davuluri Ramana; Weinstein Michael; Marcucci Guido; Caligiuri Michael A
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.
Immunity 2006;24(5):575-90.
2006: Farag Sherif S; Caligiuri Michael A
Human natural killer cell development and biology.
Blood reviews 2006;20(3):123-37.
2006: Monk J Paul; Phillips Gary; Waite Ross; Kuhn John; Schaaf Larry J; Otterson Gregory A; Guttridge Denis; Rhoades Chris; Shah Manisha; Criswell Tamara; Caligiuri Michael A; Villalona-Calero Miguel A
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1852-9.
2006: Farag Sherif S; Caligiuri Michael A
Immunologic approaches to acute leukemia in the elderly.
Seminars in hematology 2006;43(2):118-25.
2006: Freud Aharon G; Yokohama Akihiko; Becknell Brian; Lee Melissa T; Mao Hsiaoyin C; Ferketich Amy K; Caligiuri Michael A
Evidence for discrete stages of human natural killer cell differentiation in vivo.
The Journal of experimental medicine 2006;203(4):1033-43.
2006: VanDeusen Jeffrey B; Shah Manisha H; Becknell Brian; Blaser Bradley W; Ferketich Amy K; Nuovo Gerard J; Ahmer Brian M M; Durbin Joan; Caligiuri Michael A
STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo.
European journal of immunology 2006;36(3):623-30.
2006: Glaser Ronald; Litsky Monica L; Padgett David A; Baiocchi Robert A; Yang Eric V; Chen Min; Yeh Peir-En; Green-Church Kari B; Caligiuri Michael A; Williams Marshall V
EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease.
Virology 2006;346(1):205-18.
2006: Notari Mario; Neviani Paolo; Santhanam Ramasamy; Blaser Bradley W; Chang Ji-Suk; Galietta Annamaria; Willis Anne E; Roy Denis C; Caligiuri Michael A; Marcucci Guido; Perrotti Danilo
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Blood 2006;107(6):2507-16.
2006: Caligiuri Michael A
Recent advances in the treatment of transplant-related lymphoma.
Clinical advances in hematology & oncology : H&O 2006;4(1):32-3.
2006: Byrd John C; Gribben John G; Peterson Bercedis L; Grever Michael R; Lozanski Gerard; Lucas David M; Lampson Ben; Larson Richard A; Caligiuri Michael A; Heerema Nyla A
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):437-43.
2006: Blaser Bradley W; Caligiuri Michael A
Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
Best practice & research. Clinical haematology 2006;19(2):281-92.
2005: Marcucci Guido; Baldus Claudia D; Ruppert Amy S; Radmacher Michael D; Mrózek Krzysztof; Whitman Susan P; Kolitz Jonathan E; Edwards Colin G; Vardiman James W; Powell Bayard L; Baer Maria R; Moore Joseph O; Perrotti Danilo; Caligiuri Michael A; Carroll Andrew J; Larson Richard A; de la Chapelle Albert; Bloomfield Clara D
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9234-42.
2005: Neviani Paolo; Santhanam Ramasamy; Trotta Rossana; Notari Mario; Blaser Bradley W; Liu Shujun; Mao Hsiaoyin; Chang Ji Suk; Galietta Annamaria; Uttam Ashwin; Roy Denis C; Valtieri Mauro; Bruner-Klisovic Rebecca; Caligiuri Michael A; Bloomfield Clara D; Marcucci Guido; Perrotti Danilo
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Cancer cell 2005;8(5):355-68.
2005: Mone Andrew; Puhalla Shannon; Whitman Susan; Baiocchi Robert A; Cruz Julio; Vukosavljevic Tamara; Banks Amy; Eisenbeis Charles F; Byrd John C; Caligiuri Michael A; Porcu Pierluigi
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
Blood 2005;106(10):3380-2.
2005: Lute Kenneth D; May Kenneth F; Lu Ping; Zhang Huiming; Kocak Ergun; Mosinger Bedrick; Wolford Christopher; Phillips Gary; Caligiuri Michael A; Zheng Pan; Liu Yang
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Blood 2005;106(9):3127-33.
2005: Parihar Robin; Trotta Rossana; Roda Julie M; Ferketich Amy K; Tridandapani Susheela; Caligiuri Michael A; Carson William E
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
Cancer research 2005;65(19):9099-107.
2005: Roychowdhury Sameek; Blaser Bradley W; Freud Aharon G; Katz Kerry; Bhatt Darshna; Ferketich Amy K; Bergdall Valerie; Kusewitt Donna; Baiocchi Robert A; Caligiuri Michael A
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.
Blood 2005;106(7):2433-5.
2005: Whitman Susan P; Liu Shujun; Vukosavljevic Tamara; Rush Laura J; Yu Li; Liu Chunhui; Klisovic Marko I; Maharry Kati; Guimond Martin; Strout Matthew P; Becknell Brian; Dorrance Adrienne; Klisovic Rebecca B; Plass Christoph; Bloomfield Clara D; Marcucci Guido; Caligiuri Michael A
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
Blood 2005;106(1):345-52.
2005: Dai Guowei; Chan Kenneth K; Liu Shujun; Hoyt Dale; Whitman Susan; Klisovic Marko; Shen Tiansheng; Caligiuri Michael A; Byrd John; Grever Michael; Marcucci Guido
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2998-3008.
2005: Trotta Rossana; Parihar Robin; Yu Jianhua; Becknell Brian; Allard Jeffrey; Wen Jing; Ding Wei; Mao Hsiaoyin; Tridandapani Susheela; Carson William E; Caligiuri Michael A
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation.
Blood 2005;105(8):3011-8.
2005: Freud Aharon G; Becknell Brian; Roychowdhury Sameek; Mao Hsiaoyin C; Ferketich Amy K; Nuovo Gerard J; Hughes Tiffany L; Marburger Trent B; Sung John; Baiocchi Robert A; Guimond Martin; Caligiuri Michael A
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.
Immunity 2005;22(3):295-304.
2005: Yu Li; Liu Chunhui; Vandeusen Jeff; Becknell Brian; Dai Zunyan; Wu Yue-Zhong; Raval Aparna; Liu Te-Hui; Ding Wei; Mao Charlene; Liu Shujun; Smith Laura T; Lee Stephen; Rassenti Laura; Marcucci Guido; Byrd John; Caligiuri Michael A; Plass Christoph
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.
Nature genetics 2005;37(3):265-74.
2005: Dierksheide Julie E; Baiocchi Robert A; Ferketich Amy K; Roychowdhury Sameek; Pelletier Ronald P; Eisenbeis Charles F; Caligiuri Michael A; VanBuskirk Anne M
IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.
Blood 2005;105(4):1558-65.
2005: May Kenneth F; Roychowdhury Sameek; Bhatt Darshna; Kocak Ergun; Bai Xue-Feng; Liu Jin-Qing; Ferketich Amy K; Martin Edward W; Caligiuri Michael A; Zheng Pan; Liu Yang
Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.
Blood 2005;105(3):1114-20.
2005: Becknell Brian; Trotta Rossana; Yu Jianhua; Ding Wei; Mao Hsiaoyin C; Hughes Tiffany; Marburger Trent; Caligiuri Michael A
Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector.
Journal of immunological methods 2005;296(1-2):115-23.
2005: Blaser Bradley W; Roychowdhury Sameek; Kim Daniel J; Schwind Noah R; Bhatt Darshna; Yuan Weifeng; Kusewitt Donna F; Ferketich Amy K; Caligiuri Michael A; Guimond Martin
Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
Blood 2005;105(2):894-901.
2005: Roychowdhury Sameek; Caligiuri Michael A
Cytokine therapy for cancer: antigen presentation.
Cancer treatment and research 2005;123():249-66.
2005: Becknell Brian; Caligiuri Michael A
Interleukin-2, interleukin-15, and their roles in human natural killer cells.
Advances in immunology 2005;86():209-39.
2004: Roychowdhury Sameek; May Kenneth F; Tzou Katherine S; Lin Teresa; Bhatt Darshna; Freud Aharon G; Guimond Martin; Ferketich Amy K; Liu Yang; Caligiuri Michael A
Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Cancer research 2004;64(21):8062-7.
2004: Kolitz Jonathan E; George Stephen L; Dodge Richard K; Hurd David D; Powell Bayard L; Allen Steven L; Velez-Garcia Enrique; Moore Joseph O; Shea Thomas C; Hoke Eva; Caligiuri Michael A; Vardiman James W; Bloomfield Clara D; Larson Richard A;
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4290-301.
2004: Yu Li; Liu Chunhui; Bennett Kristi; Wu Yue-Zhong; Dai Zunyan; Vandeusen Jeff; Opavsky Rene; Raval Aparna; Trikha Prashant; Rodriguez Ben; Becknell Brian; Mao Charlene; Lee Stephen; Davuluri Ramana V; Leone Gustavo; Van den Veyver Ignatia B; Caligiuri Michael A; Plass Christoph
A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.
Genomics 2004;84(4):647-60.
2004: Roychowdhury Sameek; Baiocchi Robert A; Vourganti Srinivas; Bhatt Darshna; Blaser Bradley W; Freud Aharon G; Chou Jason; Chen Chang-Shi; Xiao Jim J; Parthun Mark; Chan Kenneth K; Eisenbeis Charles F; Ferketich Amy K; Grever Michael R; Chen Ching-Shih; Caligiuri Michael A
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Journal of the National Cancer Institute 2004;96(19):1447-57.
2004: Eisenbeis Charles F; Grainger Andrew; Fischer Beth; Baiocchi Robert A; Carrodeguas Lester; Roychowdhury Sameek; Chen Lei; Banks Amy L; Davis Thomas; Young Donn; Kelbick Nicole; Stephens Julie; Byrd John C; Grever Michael R; Caligiuri Michael A; Porcu Pierluigi
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6101-10.
2004: Cooper Megan A; Caligiuri Michael A
Isolation and characterization of human natural killer cell subsets.
Current protocols in immunology / edited by John E. Coligan ... [et al.] 2004;Chapter 7():Unit 7.34.
2004: Baldus Claudia D; Liyanarachchi Sandya; Mrózek Krzysztof; Auer Herbert; Tanner Stephan M; Guimond Martin; Ruppert Amy S; Mohamed Nehad; Davuluri Ramana V; Caligiuri Michael A; Bloomfield Clara D; de la Chapelle Albert
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(11):3915-20.
2004: Cooper Megan A; Fehniger Todd A; Fuchs Anja; Colonna Marco; Caligiuri Michael A
NK cell and DC interactions.
Trends in immunology 2004;25(1):47-52.
2004: Farag Sherif S; Caligiuri Michael A
Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.
Advances in pharmacology (San Diego, Calif.) 2004;51():295-318.
2004: Marcucci G; Stock W; Dai G; Klisovic M I; Maharry K; Shen T; Liu S; Sher D A; Lucas D; Zwiebel A; Larson R A; Caligiuri M A; Bloomfield C D; Chan K K; Grever M R; Byrd J C
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Annals of hematology 2004;83 Suppl 1():S93-4.
2003: Becknell Brian; Shen Tiansheng; Maghraby Eman; Taya Shinichiro; Kaibuchi Kozo; Caligiuri Michael A; Marcucci Guido
Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development.
Cell and tissue research 2003;314(3):361-6.
2003: Gao Jian-Xin; Liu Xingluo; Wen Jing; Caligiuri Michael A; Stroynowski Iwona; Zheng Pan; Liu Yang
Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells.
Blood 2003;102(13):4456-63.
2003: Baldus Claudia D; Tanner Stephan M; Kusewitt Donna F; Liyanarachchi Sandya; Choi Changsun; Caligiuri Michael A; Bloomfield Clara D; de la Chapelle Albert
BAALC, a novel marker of human hematopoietic progenitor cells.
Experimental hematology 2003;31(11):1051-6.
2003: Marcucci Guido; Caligiuri Michael A; Bloomfield Clara D
Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
European journal of haematology 2003;71(3):143-54.
2003: Baldus Claudia D; Tanner Stephan M; Ruppert Amy S; Whitman Susan P; Archer Kellie J; Marcucci Guido; Caligiuri Michael A; Carroll Andrew J; Vardiman James W; Powell Bayard L; Allen Steven L; Moore Joseph O; Larson Richard A; Kolitz Jonathan E; de la Chapelle Albert; Bloomfield Clara D
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Blood 2003;102(5):1613-8.
2003: Farag Sherif S; VanDeusen Jeffrey B; Fehniger Todd A; Caligiuri Michael A
Biology and clinical impact of human natural killer cells.
International journal of hematology 2003;78(1):7-17.
2003: Griffin John H; Leung Joey; Bruner Rebecca J; Caligiuri Michael A; Briesewitz Roger
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(13):7830-5.
2003: Tridandapani Susheela; Wardrop Richard; Baran Christopher P; Wang Yijie; Opalek Judy M; Caligiuri Michael A; Marsh Clay B
TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(9):4572-7.
2003: Marcucci Guido; Perrotti Danilo; Caligiuri Michael A
Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1248-52.
2003: Farag Sherif S; Fehniger Todd A; Becknell Brian; Blaser Bradley W; Caligiuri Michael A
New directions in natural killer cell-based immunotherapy of human cancer.
Expert opinion on biological therapy 2003;3(2):237-50.
2003: Fehniger Todd A; Cooper Megan A; Nuovo Gerard J; Cella Marina; Facchetti Fabio; Colonna Marco; Caligiuri Michael A
CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.
Blood 2003;101(8):3052-7.
2003: Roychowdhury Sameek; Peng Ruoqi; Baiocchi Robert A; Bhatt Darshna; Vourganti Srinivas; Grecula John; Gupta Nilendu; Eisenbeis Charles F; Nuovo Gerard J; Yang Weilian; Schmalbrock Petra; Ferketich Amy; Moeschberger Melvin; Porcu Pierluigi; Barth Rolf F; Caligiuri Michael A
Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
Cancer research 2003;63(5):965-71.
2003: Trotta Rossana; Vignudelli Tatiana; Candini Olivia; Intine Robert V; Pecorari Luisa; Guerzoni Clara; Santilli Giorgia; Byrom Mike W; Goldoni Silvia; Ford Lance P; Caligiuri Michael A; Maraia Richard J; Perrotti Danilo; Calabretta Bruno
BCR/ABL activates mdm2 mRNA translation via the La antigen.
Cancer cell 2003;3(2):145-60.
2003: VanDeusen Jeffrey B; Caligiuri Michael A
New developments in anti-tumor efficacy and malignant transformation of human natural killer cells.
Current opinion in hematology 2003;10(1):55-9.
2003: Ladner Katherine J; Caligiuri Michael A; Guttridge Denis C
Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products.
The Journal of biological chemistry 2003;278(4):2294-303.
2003: Marcucci Guido; Byrd John C; Dai Guowei; Klisovic Marko I; Kourlas Peter J; Young Donn C; Cataland Spero R; Fisher Diane B; Lucas David; Chan Kenneth K; Porcu Pierluigi; Lin Zhong-Pin; Farag Sherif F; Frankel Stanley R; Zwiebel James A; Kraut Eric H; Balcerzak Stanley P; Bloomfield Clara D; Grever Michael R; Caligiuri Michael A
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Blood 2003;101(2):425-32.
2003: Shah Manisha H; Porcu Pierluigi; Mallery Susan R; Caligiuri Michael A
AIDS-associated malignancies.
Cancer chemotherapy and biological response modifiers 2003;21():717-46.
2002: Yang Weilian; Barth Rolf F; Adams Dianne M; Ciesielski Michael J; Fenstermaker Robert A; Shukla Supriya; Tjarks Werner; Caligiuri Michael A
Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
Cancer research 2002;62(22):6552-8.
2002: Cooper Megan A; Bush Jennifer E; Fehniger Todd A; VanDeusen Jeffrey B; Waite Ross E; Liu Yang; Aguila Hector L; Caligiuri Michael A
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.
Blood 2002;100(10):3633-8.
2002: Porcu Pierluigi; Eisenbeis Charles F; Pelletier Ronald P; Davies Elizabeth A; Baiocchi Robert A; Roychowdhury Sameek; Vourganti Srinivas; Nuovo Gerard J; Marsh William L; Ferketich Amy K; Henry Mitchell L; Ferguson Ronald M; Caligiuri Michael A
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
Blood 2002;100(7):2341-8.
2002: Farag Sherif S; George Stephen L; Lee Edward J; Baer Maria; Dodge Richard K; Becknell Brian; Fehniger Todd A; Silverman Lewis R; Crawford Jeffrey; Bloomfield Clara D; Larson Richard A; Schiffer Charles A; Caligiuri Michael A
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2812-9.
2002: Farag Sherif S; Fehniger Todd A; Ruggeri Loredana; Velardi Andrea; Caligiuri Michael A
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.
Blood 2002;100(6):1935-47.
2002: Baer Maria R; George Stephen L; Dodge Richard K; O'Loughlin Kieran L; Minderman Hans; Caligiuri Michael A; Anastasi John; Powell Bayard L; Kolitz Jonathan E; Schiffer Charles A; Bloomfield Clara D; Larson Richard A
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Blood 2002;100(4):1224-32.
2002: Cooper M A; Caligiuri M A
Immunologic manipulation in AML: from bench to bedside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):736-7.
2002: Fehniger Todd A; Cooper Megan A; Caligiuri Michael A
Interleukin-2 and interleukin-15: immunotherapy for cancer.
Cytokine & growth factor reviews 2002;13(2):169-83.
2002: Biber Jennifer L; Jabbour Saad; Parihar Robin; Dierksheide Julie; Hu Yan; Baumann Heinz; Bouchard Page; Caligiuri Michael A; Carson William
Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma.
Cellular immunology 2002;216(1-2):31-42.
2002: Rush Laura J; Heinonen Kristiina; Mrózek Krzysztof; Wolf Brian J; Abdel-Rahman Mohamed; Szymanska Jadwiga; Peltomäki Paivi; Kapadia Fehmida; Bloomfield Clara D; Caligiuri Michael A; Plass Christoph
Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line.
Blood 2002;99(5):1874-6.
2002: Perrotti Danilo; Cesi Vincenzo; Trotta Rossana; Guerzoni Clara; Santilli Giorgia; Campbell Kenneth; Iervolino Angela; Condorelli Fabrizio; Gambacorti-Passerini Carlo; Caligiuri Michael A; Calabretta Bruno
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Nature genetics 2002;30(1):48-58.
2002: Shah Manisha H; Porcu Pierluigi; Mallery Susan R; Caligiuri Michael A
AIDS-associated malignancies.
Cancer chemotherapy and biological response modifiers 2002;20():633-64.
2002: Farag S S; Fehniger T; Ruggeri L; Velardi A; Caligiuri M A
Natural killer cells: biology and application in stem-cell transplantation.
Cytotherapy 2002;4(5):445-6.
2001: Comella K; Nakamura M; Melnik K; Chosy J; Zborowski M; Cooper M A; Fehniger T A; Caligiuri M A; Chalmers J J
Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system.
Cytometry 2001;45(4):285-93.
2001: Tanner S M; Austin J L; Leone G; Rush L J; Plass C; Heinonen K; Mrózek K; Sill H; Knuutila S; Kolitz J E; Archer K J; Caligiuri M A; Bloomfield C D; de La Chapelle A
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):13901-6.
2001: Cooper M A; Fehniger T A; Caligiuri M A
The biology of human natural killer-cell subsets.
Trends in immunology 2001;22(11):633-40.
2001: Carson W E; Parihar R; Lindemann M J; Personeni N; Dierksheide J; Meropol N J; Baselga J; Caligiuri M A
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
European journal of immunology 2001;31(10):3016-25.
2001: Whitman S P; Archer K J; Feng L; Baldus C; Becknell B; Carlson B D; Carroll A J; Mrózek K; Vardiman J W; George S L; Kolitz J E; Larson R A; Bloomfield C D; Caligiuri M A
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Cancer research 2001;61(19):7233-9.
2001: Baiocchi R A; Ward J S; Carrodeguas L; Eisenbeis C F; Peng R; Roychowdhury S; Vourganti S; Sekula T; O'Brien M; Moeschberger M; Caligiuri M A
GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.
The Journal of clinical investigation 2001;108(6):887-94.
2001: Marcucci G; Caligiuri M A; Döhner H; Archer K J; Schlenk R F; Döhner K; Maghraby E A; Bloomfield C D
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(7):1072-80.
2001: Fehniger T A; Caligiuri M A
Ontogeny and expansion of human natural killer cells: clinical implications.
International reviews of immunology 2001;20(3-4):503-34.
2001: Smiraglia D J; Rush L J; Frühwald M C; Dai Z; Held W A; Costello J F; Lang J C; Eng C; Li B; Wright F A; Caligiuri M A; Plass C
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies.
Human molecular genetics 2001;10(13):1413-9.
2001: Rush L J; Dai Z; Smiraglia D J; Gao X; Wright F A; Frühwald M; Costello J F; Held W A; Yu L; Krahe R; Kolitz J E; Bloomfield C D; Caligiuri M A; Plass C
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci.
Blood 2001;97(10):3226-33.
2001: Cooper M A; Fehniger T A; Turner S C; Chen K S; Ghaheri B A; Ghayur T; Carson W E; Caligiuri M A
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
Blood 2001;97(10):3146-51.
2001: Mrózek K; Prior T W; Edwards C; Marcucci G; Carroll A J; Snyder P J; Koduru P R; Theil K S; Pettenati M J; Archer K J; Caligiuri M A; Vardiman J W; Kolitz J E; Larson R A; Bloomfield C D
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2482-92.
2001: Cooper M A; Fehniger T A; Ponnappan A; Mehta V; Wewers M D; Caligiuri M A
Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
European journal of immunology 2001;31(3):792-801.
2001: Fehniger T A; Suzuki K; VanDeusen J B; Cooper M A; Freud A G; Caligiuri M A
Fatal leukemia in interleukin-15 transgenic mice.
Blood cells, molecules & diseases 2001;27(1):223-30.
2001: Fehniger T A; Suzuki K; Ponnappan A; VanDeusen J B; Cooper M A; Florea S M; Freud A G; Robinson M L; Durbin J; Caligiuri M A
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.
The Journal of experimental medicine 2001;193(2):219-31.
2001: Whitman S P; Strout M P; Marcucci G; Freud A G; Culley L L; Zeleznik-Le N J; Mrózek K; Theil K S; Kees U R; Bloomfield C D; Caligiuri M A
The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia.
Cancer research 2001;61(1):59-63.
2001: Virtaneva K; Wright F A; Tanner S M; Yuan B; Lemon W J; Caligiuri M A; Bloomfield C D; de La Chapelle A; Krahe R
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(3):1124-9.
2001: Fehniger T A; Caligiuri M A
Interleukin 15: biology and relevance to human disease.
Blood 2001;97(1):14-32.
2000: Porcu P; Caligiuri M A
Acquired immunodeficiency syndrome-related lymphomas: future directions.
Seminars in oncology 2000;27(4):454-62.
2000: Carson W E; Dierksheide J E; Jabbour S; Anghelina M; Bouchard P; Ku G; Yu H; Baumann H; Shah M H; Cooper M A; Durbin J; Caligiuri M A
Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction.
Blood 2000;96(4):1465-73.
2000: Fehniger T A; Bluman E M; Porter M M; Mrózek E; Cooper M A; VanDeusen J B; Frankel S R; Stock W; Caligiuri M A
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
The Journal of clinical investigation 2000;106(1):117-24.
2000: Shah M H; Baiocchi R A; Fehniger T A; Khatri V P; Gould M; Poiesz B; Bernstein Z P; Caligiuri M A
Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: the rationale for low-dose interleukin-2 therapy.
The cancer journal from Scientific American 2000;6 Suppl 1():S45-51.
2000: Kourlas P J; Strout M P; Becknell B; Veronese M L; Croce C M; Theil K S; Krahe R; Ruutu T; Knuutila S; Bloomfield C D; Caligiuri M A
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(5):2145-50.
2000: Fehniger T A; Yu H; Cooper M A; Suzuki K; Shah M H; Caligiuri M A
Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(4):1643-7.
2000: Costello J F; Frühwald M C; Smiraglia D J; Rush L J; Robertson G P; Gao X; Wright F A; Feramisco J D; Peltomäki P; Lang J C; Schuller D E; Yu L; Bloomfield C D; Caligiuri M A; Yates A; Nishikawa R; Su Huang H; Petrelli N J; Zhang X; O'Dorisio M S; Held W A; Cavenee W K; Plass C
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.
Nature genetics 2000;24(2):132-8.
1999: Baiocchi R A; Caligiuri M A
Cytokines in the evolution and treatment of AIDS-lymphoma.
Current opinion in oncology 1999;11(6):516-21.
1999: Khatri V P; Baiocchi R A; Peng R; Oberkircher A R; Dolce J M; Ward P M; Herzig G P; Caligiuri M A
Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):500-6.
1999: Strout M P; Marcucci G; Caligiuri M A; Bloomfield C D
Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications.
Annals of hematology 1999;78(6):251-64.
1999: Plass C; Yu F; Yu L; Strout M P; El-Rifai W; Elonen E; Knuutila S; Marcucci G; Young D C; Held W A; Bloomfield C D; Caligiuri M A
Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene.
Oncogene 1999;18(20):3159-65.
1999: Fehniger T A; Carson W E; Caligiuri M A
Costimulation of human natural killer cells is required for interferon gamma production.
Transplantation proceedings 1999;31(3):1476-8.
1999: Carson W E; Yu H; Dierksheide J; Pfeffer K; Bouchard P; Clark R; Durbin J; Baldwin A S; Peschon J; Johnson P R; Ku G; Baumann H; Caligiuri M A
A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4943-51.
1999: Fehniger T A; Shah M H; Turner M J; VanDeusen J B; Whitman S P; Cooper M A; Suzuki K; Wechser M; Goodsaid F; Caligiuri M A
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4511-20.
1998: Fehniger T A; Herbein G; Yu H; Para M I; Bernstein Z P; O'Brien W A; Caligiuri M A
Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6433-8.
1998: Yu H; Fehniger T A; Fuchshuber P; Thiel K S; Vivier E; Carson W E; Caligiuri M A
Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.
Blood 1998;92(10):3647-57.
1998: Marcucci G; Livak K J; Bi W; Strout M P; Bloomfield C D; Caligiuri M A
Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(9):1482-9.
1998: Meropol N J; Barresi G M; Fehniger T A; Hitt J; Franklin M; Caligiuri M A
Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Cancer immunology, immunotherapy : CII 1998;46(6):318-26.
1998: Khatri V P; Caligiuri M A
A review of the association between interleukin-10 and human B-cell malignancies.
Cancer immunology, immunotherapy : CII 1998;46(5):239-44.
1998: Frey M; Packianathan N B; Fehniger T A; Ross M E; Wang W C; Stewart C C; Caligiuri M A; Evans S S
Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(1):400-8.
1998: Shah M H; Hackshaw K V; Caligiuri M A
A role for IL-15 in rheumatoid arthritis?
Nature medicine 1998;4(6):643.
1998: Khatri V P; Fehniger T A; Baiocchi R A; Yu F; Shah M H; Schiller D S; Gould M; Gazzinelli R T; Bernstein Z P; Caligiuri M A
Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
The Journal of clinical investigation 1998;101(6):1373-8.
1998: Strout M P; Marcucci G; Bloomfield C D; Caligiuri M A
The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(5):2390-5.
1998: Marcucci G; Strout M P; Bloomfield C D; Caligiuri M A
Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts.
Cancer research 1998;58(4):790-3.
1998: Carson W; Caligiuri M A
Interleukin-15 as a potential regulator of the innate immune response.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1998;31(1):1-9.
1998: Caligiuri M A; Strout M P; Lawrence D; Arthur D C; Baer M R; Yu F; Knuutila S; Mrózek K; Oberkircher A R; Marcucci G; de la Chapelle A; Elonen E; Block A W; Rao P N; Herzig G P; Powell B L; Ruutu T; Schiffer C A; Bloomfield C D
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
Cancer research 1998;58(1):55-9.
1997: Khatri V P; Baiocchi R A; Bernstein Z P; Caligiuri M A
Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.
The cancer journal from Scientific American 1997;3 Suppl 1():S129-36.
1997: Marcucci G; Caligiuri M A; Bloomfield C D
Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions.
Blood 1997;90(12):5022-5024.
1997: Fehniger T A; Carson W E; Mrózek E; Caligiuri M A
Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
Blood 1997;90(9):3647-53.
1997: Baiocchi R A; Khatri V P; Lindemann M J; Ross M E; Papoff G; Caprio A J; Caprio T V; Fenstermaker R; Ruberti G; Bernstein Z P; Caligiuri M A
Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome.
Blood 1997;90(5):1737-46.
1997: Jurlander J; Lai C F; Tan J; Chou C C; Geisler C H; Schriber J; Blumenson L E; Narula S K; Baumann H; Caligiuri M A
Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells.
Blood 1997;89(11):4146-52.
1997: Caligiuri M A; Strout M P; Oberkircher A R; Yu F; de la Chapelle A; Bloomfield C D
The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):3899-902.
1997: Carson W E; Fehniger T A; Caligiuri M A
CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
European journal of immunology 1997;27(2):354-60.
1997: Caligiuri M A; Strout M P; Gilliland D G
Molecular biology of acute myeloid leukemia.
Seminars in oncology 1997;24(1):32-44.
1997: Ross M E; Caligiuri M A
Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response.
Blood 1997;89(3):910-8.
1997: Strout M P; Caligiuri M A
Developments in cytogenetics and oncogenes in acute leukemia.
Current opinion in oncology 1997;9(1):8-17.
1996: Carson W E; Caligiuri M A
Interleukin 15: a potential player during the innate immune response to infection.
Experimental parasitology 1996;84(2):291-4.
1996: Bluman E M; Schnier G S; Avalos B R; Strout M P; Sultan H; Jacobson F W; Williams D E; Carson W E; Caligiuri M A
The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction.
Blood 1996;88(10):3887-93.
1996: Bullrich F; Veronese M L; Kitada S; Jurlander J; Caligiuri M A; Reed J C; Croce C M
Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia.
Blood 1996;88(8):3109-15.
1996: Soni N; Meropol N J; Porter M; Caligiuri M A
Diabetes mellitus induced by low-dose interleukin-2.
Cancer immunology, immunotherapy : CII 1996;43(1):59-62.
1996: Jurlander J; Caligiuri M A; Ruutu T; Baer M R; Strout M P; Oberkircher A R; Hoffmann L; Ball E D; Frei-Lahr D A; Christiansen N P; Block A M; Knuutila S; Herzig G P; Bloomfield C D
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
Blood 1996;88(6):2183-91.
1996: Bluman E M; Bartynski K J; Avalos B R; Caligiuri M A
Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines.
The Journal of clinical investigation 1996;97(12):2722-7.
1996: Lai C F; Ripperger J; Morella K K; Jurlander J; Hawley T S; Carson W E; Kordula T; Caligiuri M A; Hawley R G; Fey G H; Baumann H
Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements.
The Journal of biological chemistry 1996;271(24):13968-75.
1996: Mrózek E; Anderson P; Caligiuri M A
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells.
Blood 1996;87(7):2632-40.
1996: Caligiuri M A; Strout M P; Schichman S A; Mrózek K; Arthur D C; Herzig G P; Baer M R; Schiffer C A; Heinonen K; Knuutila S; Nousiainen T; Ruutu T; Block A W; Schulman P; Pedersen-Bjergaard J; Croce C M; Bloomfield C D
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.
Cancer research 1996;56(6):1418-25.
1995: Carson W E; Ross M E; Baiocchi R A; Marien M J; Boiani N; Grabstein K; Caligiuri M A
Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro.
The Journal of clinical investigation 1995;96(6):2578-82.
1995: Oberkircher A R; Strout M P; Herzig G P; Fritz P D; Caligiuri M A
Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation.
Bone marrow transplantation 1995;16(5):695-702.
1995: Bernstein Z P; Porter M M; Gould M; Lipman B; Bluman E M; Stewart C C; Hewitt R G; Fyfe G; Poiesz B; Caligiuri M A
Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
Blood 1995;86(9):3287-94.
1995: Carson W E; Lindemann M J; Baiocchi R; Linett M; Tan J C; Chou C C; Narula S; Caligiuri M A
The functional characterization of interleukin-10 receptor expression on human natural killer cells.
Blood 1995;85(12):3577-85.
1994: Carson W E; Giri J G; Lindemann M J; Linett M L; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri M A
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
The Journal of experimental medicine 1994;180(4):1395-403.
1994: Schichman S A; Caligiuri M A; Strout M P; Carter S L; Gu Y; Canaani E; Bloomfield C D; Croce C M
ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements.
Cancer research 1994;54(16):4277-80.
1994: Carson W E; Haldar S; Baiocchi R A; Croce C M; Caligiuri M A
The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(16):7553-7.
1994: Schichman S A; Caligiuri M A; Gu Y; Strout M P; Canaani E; Bloomfield C D; Croce C M
ALL-1 partial duplication in acute leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(13):6236-9.
1994: Baiocchi R A; Caligiuri M A
Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(12):5577-81.
1994: Beecher M S; Baiocchi R A; Linett M L; Krajewski C A; Caligiuri M A
Expression of the zeta protein subunit in CD3- NK effectors derived from human thymus.
Cellular immunology 1994;155(2):508-16.
1994: Caligiuri M A; Schichman S A; Strout M P; Mrózek K; Baer M R; Frankel S R; Barcos M; Herzig G P; Croce C M; Bloomfield C D
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations.
Cancer research 1994;54(2):370-3.
1993: Matos M E; Schnier G S; Beecher M S; Ashman L K; William D E; Caligiuri M A
Expression of a functional c-kit receptor on a subset of natural killer cells.
The Journal of experimental medicine 1993;178(3):1079-84.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Michael Caligiuri

Research Profile (preview)

Anatomy

Living Beings

Chemicals & Drugs

Disorders

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Michael Caligiuri (preview)

All Publications